Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assertio Holdings, Inc. stock logo
ASRT
Assertio
$0.68
+3.5%
$0.65
$0.51
$1.80
$64.75M0.29344,962 shs40,696 shs
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$4.97
-2.6%
$5.23
$3.79
$14.60
$248.50M-0.911.48 million shs139,586 shs
LIMN
Liminatus Pharma
$8.42
-6.7%
$0.00
$4.40
$33.66
$219.00MN/A351,476 shs60,792 shs
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$24.18
+0.2%
$23.29
$6.20
$29.27
$267.43M-0.1179,193 shs8,430 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assertio Holdings, Inc. stock logo
ASRT
Assertio
0.00%+4.95%+2.90%+15.74%-52.71%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
0.00%+4.08%-15.56%+5.37%-12.37%
LIMN
Liminatus Pharma
0.00%-4.85%+901,999,900.00%+901,999,900.00%+901,999,900.00%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
0.00%+9.24%-5.04%+20.18%+2,411,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Assertio Holdings, Inc. stock logo
ASRT
Assertio
1.6379 of 5 stars
3.50.00.00.01.10.81.3
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
2.4715 of 5 stars
3.51.00.00.03.31.70.6
LIMN
Liminatus Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
3.3999 of 5 stars
3.60.00.00.02.84.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Assertio Holdings, Inc. stock logo
ASRT
Assertio
3.00
Buy$2.75306.80% Upside
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
3.00
Buy$22.00343.10% Upside
LIMN
Liminatus Pharma
0.00
N/AN/AN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
3.13
Buy$46.2991.42% Upside

Current Analyst Ratings Breakdown

Latest ASRT, LIMN, CADL, and PVLA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$23.00
5/19/2025
Assertio Holdings, Inc. stock logo
ASRT
Assertio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.50 ➝ $3.50
5/16/2025
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$53.00 ➝ $52.00
5/13/2025
Assertio Holdings, Inc. stock logo
ASRT
Assertio
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/30/2025
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
4/11/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
4/9/2025
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$50.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Assertio Holdings, Inc. stock logo
ASRT
Assertio
$124.96M0.52$0.05 per share13.30$1.27 per share0.53
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$120K2,072.89N/AN/A$1.41 per share3.52
LIMN
Liminatus Pharma
N/AN/AN/AN/AN/AN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$42.81M6.25N/AN/A$5.58 per share4.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Assertio Holdings, Inc. stock logo
ASRT
Assertio
-$21.58M-$0.32N/A22.53N/A-25.72%-24.87%-10.87%8/6/2025 (Estimated)
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$55.18M-$1.34N/AN/AN/AN/A-136.74%-63.13%8/12/2025 (Estimated)
LIMN
Liminatus Pharma
N/AN/A0.00N/AN/AN/AN/AN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-$17.43M-$12.10N/AN/AN/AN/A-60.29%-43.30%8/13/2025 (Estimated)

Latest ASRT, LIMN, CADL, and PVLA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-$3.40-$0.74+$2.66-$0.74N/AN/A
5/13/2025Q1 2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$0.24$0.13+$0.37$0.13N/AN/A
5/12/2025Q1 2025
Assertio Holdings, Inc. stock logo
ASRT
Assertio
-$0.06-$0.14-$0.08-$0.14$27.52 million$26.49 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Assertio Holdings, Inc. stock logo
ASRT
Assertio
N/AN/AN/AN/AN/A
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
N/AN/AN/AN/AN/A
LIMN
Liminatus Pharma
N/AN/AN/AN/AN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Assertio Holdings, Inc. stock logo
ASRT
Assertio
0.36
1.66
1.35
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
0.01
4.64
4.64
LIMN
Liminatus Pharma
N/AN/AN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
N/A
8.84
8.84

Institutional Ownership

CompanyInstitutional Ownership
Assertio Holdings, Inc. stock logo
ASRT
Assertio
48.96%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
13.93%
LIMN
Liminatus Pharma
N/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
40.11%

Insider Ownership

CompanyInsider Ownership
Assertio Holdings, Inc. stock logo
ASRT
Assertio
4.00%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
16.60%
LIMN
Liminatus Pharma
N/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
20.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Assertio Holdings, Inc. stock logo
ASRT
Assertio
2095.78 million91.95 millionOptionable
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
6050.10 million41.79 millionOptionable
LIMN
Liminatus Pharma
N/A26.01 millionN/AN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
N/A11.06 million8.79 millionN/A

Recent News About These Companies

Cantor Fitzgerald Comments on PVLA FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Assertio stock logo

Assertio NASDAQ:ASRT

$0.68 +0.02 (+3.52%)
As of 11:06 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Candel Therapeutics stock logo

Candel Therapeutics NASDAQ:CADL

$4.96 -0.14 (-2.65%)
As of 11:07 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Liminatus Pharma NASDAQ:LIMN

$8.42 -0.60 (-6.65%)
As of 10:37 AM Eastern

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

Palvella Therapeutics stock logo

Palvella Therapeutics NASDAQ:PVLA

$24.18 +0.06 (+0.25%)
As of 10:45 AM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.